Table 5. Percentage of data points where medicines were both available and affordable, by World Bank Income Group.
| World Bank Income Group | Therapeutic group | Medicines available and affordable* | |||
|---|---|---|---|---|---|
| Public sector | Private sector | ||||
| Originator brand | Lowest priced generic | Originator brand | Lowest priced generic | ||
| Low-income countries (n = 10) | Cardiovascular | 3.2% (1/31) | 11.9% (5/42) | 3.3% (1/30) | 22.0% (9/41) |
| Diabetes | 0.0% (0/14) | 16.7% (3/18) | 7.1%(1/14) | 27.8%(5/18) | |
| COPD | 0.0% (0/13) | 23.5% (4/17) | 7.7%(1/13) | 17.6%(3/17) | |
| CNS | 5.0% (1/20) | 14.3% (5/35) | 5.0%(1/20) | 11.4%(4/35) | |
| All medicines for all therapeutic groups | 2.6% (2/78) | 15.2% (17/112) | 5.2%(4/77) | 18.9%(21/111) | |
| Lower-middle income countries (n = 12) | Cardiovascular | 0.0% (0/52) | 33.8% (27/80) | 1.6%(1/62) | 36.7%(33/90) |
| Diabetes | 0.0% (0/18) | 20.8% (5/24) | 0.0% (0/20) | 23.1%(6/26) | |
| COPD | 0.0% (0/18) | 21.1% (4/19) | 5.0%(1/20) | 9.1% (2/22) | |
| CNS | 2.8% (1/36) | 10.2% (5/49) | 0.0%(0/39) | 5.8%(3/52) | |
| All medicines for all therapeutic groups | 0.8% (1/124) | 23.8% (41/172) | 1.4%(2/141) | 23.2%(44/190) | |
| Upper-middle income countries (n = 8) | Cardiovascular | 0.0% (0/49) | 34.5%(20/58) | 20.4%(10/49) | 50.9%(28/55) |
| Diabetes | 0.0% (0/17) | 45.5% (10/22) | 11.8% (2/17) | 31.8% (7/22) | |
| COPD | 0.0% (0/14) | 35.7% (5/14) | 14.3% (2/14) | 35.7% (5/14) | |
| CNS | 0.0% (0/37) | 33.3% (14/42) | 5.4% (2/37) | 29.3% (12/41) | |
| All medicines for all therapeutic groups | 0.0% (0/117) | 36.0% (49/136) | 13.7% (16/117) | 39.4% (52/132) | |
*80% or greater availability and requiring 1 days’ wages or less to purchase 30 days’ supply or supplied free-of-charge in the public sector.